Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Product menu

Trelegy Ellipta pack shot
At £44.50 Trelegy Ellipta costs less than commonly prescribed multiple inhaler triple therapies in the UK.1,2

Cost of Trelegy Ellipta compared to other branded multiple inhaler triple therapy combinations in COPD.1,2

Trelegy cost table comparison
Trelegy cost comparison graph

NB: All doses stated are delivered doses. Other triple therapy options are available. BDP, beclomethasone; FOR, formoterol; BUD, budesonide; TIO, tiotropium, FF, fluticasone furoate; VI, vilanterol; UMEC, umeclidinium

Get started with Trelegy Ellipta

Order demo device

PATIENT RESOURCES

Three molecules

Molecules Matter

Learn more about the molecules inside Trelegy Ellipta

LEARN MORE
Ellipta opening

Easy-to-use Ellipta device3-5

Trelegy is delivered in the easy-to-use Ellipta device3-5. See how it compares to other commonly prescribed inhaler devices.

LEARN MORE
Guidelines open book

NICE Guidelines on COPD

What does NICE say about the appropriate time to prescribe triple therapy?

LEARN MORE

Prescribing Information

Trelegy Ellipta Prescribing Information (PDF)

Relvar Ellipta prescribing information (PDF)

Incruse Ellipta prescribing information (PDF)

Footnotes

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.6

Relvar Ellipta 92/22mcg is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilation therapy.7

Incruse Ellipta OD is indicated for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)8

References

  1. MIMS Available at: https://www.mims.co.uk/. (Accessed November 2021)
  2. IQIVIA - most commonly prescribed multiple inhaler triple therapy combinations in COPD UK
  3. Svedsater H et al BMC Pulm Med 2013; 13:1–14.
  4. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
  5. Riley JH et al. Int J Chron Obstruct Pulm Dis 2016; 11:1873–1880.
  6. Trelegy Ellipta SmPC
  7. Relvar Ellipta SmPC
  8. Incruse Ellipta SmPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

August 2022 | PM-GB-FVU-WCNT-200006 (V4.0)